BRIDGEBIO PHARMA, INC.

(BBIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO

01/17/2022 | 07:55pm EDT

NEW YORK, Jan. 17, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. ("BridgeBio" or the "Company") (NASDAQ: BBIO).  Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether BridgeBio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On December 27, 2021, BridgeBio issued a press release "announc[ing] topline results from Month 12 (Part A) of ATTRibute-CM, an ongoing global Phase 3 study investigating acoramidis for the treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM)."  BridgeBio's press release disclosed that the study failed to meet its primary endpoint. 

On this news, BridgeBio's stock price fell $29.24 per share, or 71.98%, to close at $11.38 per share on December 27, 2021.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-bridgebio-pharma-inc---bbio-301461662.html

SOURCE Pomerantz LLP


© PRNewswire 2022
All news about BRIDGEBIO PHARMA, INC.
10:48aGoldman Sachs Adjusts BridgeBio Pharma's Price Target to $19 from $24, Keeps Buy Rating
MT
05/23BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase ..
AQ
05/20BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase ..
GL
05/20BridgeBio Pharma, Inc. and Phoenix Tissue Repair, Inc Announce Positive Results from Ph..
CI
05/18BRIDGEBIO PHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct ..
AQ
05/18TRANSCRIPT : BridgeBio Pharma, Inc. Presents at Citi Biopharma VIRTUAL Co-Panel Day, May-1..
CI
05/18BridgeBio Transaction Reflects Healthy Market For FDA Priority Review Vouchers
AQ
05/17BridgeBio Pharma to Participate in May Investor Events
GL
05/17BridgeBio Pharma to Participate in May Investor Events
AQ
05/16BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million ..
AQ
More news
Analyst Recommendations on BRIDGEBIO PHARMA, INC.
More recommendations